Sutter Health is teaming up with DNAnexus, a biomedical informatics and data management company, and the University of Pittsburgh Medical Center on precision medicine research to advance treatments for multiple sclerosis, a debilitating disease that affects more than 2.3 million people worldwide.
Sutter Health is teaming up with the University of Pittsburgh Medical Center and biomedical informatics and data management company DNAnexus on precision medicine research to develop more personalized treatments for multiple sclerosis.
As part of the collaborative study, researchers at Sutter Health will collect clinical data, including electronic health record data, from patients with MS, a debilitating disease that affects more than 2.3 million people worldwide. The Genome Center at UPMC will generate genomic data from study participants’ samples, and these data will be processed and linked on the DNAnexus platform.
Sutter Health researchers, clinicians and other collaborators will use the platform to assess patients’ clinical and genomic features that correlate with MS subtypes, disability progression, staging, symptoms, MRI changes and differential response to disease-modifying therapies (DMTs), the organizations said.
|08||Read on: Sutter Health, UPMC team up on precision medicine to improve multiple sclerosis treatments|